Regulation of Lymphocyte Apoptosis by Interferon Regulatory Factor 4 (IRF-4) by Fanzo, Jessica C. et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2003/02/303/12 $8.00
Volume 197, Number 3, February 3, 2003 303–314
http://www.jem.org/cgi/doi/10.1084/jem.20020717
 
303
 
Regulation of Lymphocyte Apoptosis by Interferon 
Regulatory Factor 4 (IRF-4)
 
Jessica C. Fanzo, Chuan-Min Hu, So Young Jang, and Alessandra B. Pernis
 
Department of Molecular Medicine, Columbia University, New York, N Y 10032
 
Abstract
 
To ensure that homeostasis of the immune system is maintained, the sensitivity of lymphocytes
to Fas-mediated apoptosis is differentially regulated during their activation. The molecular
mechanisms that link the activation program of lymphocytes to changes in sensitivity to Fas-
mediated apoptosis have, however, not been fully characterized. In these studies, we have in-
vestigated whether Fas-mediated apoptosis can be regulated by interferon regulatory factor 4
(IRF-4), a lymphoid-restricted member of the IRF family of transcription factors. IRF-4 ex-
pression is upregulated during lymphocyte activation and IRF-4–deficient mice have defects in
both lymphocyte activation and homeostasis. Here, we show that stable expression of IRF-4 in
a human lymphoid cell line that normally lacks IRF-4 leads to a significantly enhanced apop-
totic response on Fas receptor engagement. A systematic examination of the downstream effec-
tors of Fas signaling in IRF-4–transfected cells demonstrates an increased activation of caspase-8,
as well as an increase in Fas receptor polarization. We demonstrate that IRF-4–deficient mice
display defects in activation-induced cell death, as well as superantigen-induced deletion, and
that these defects are accompanied by impairments in Fas receptor polarization. These data sug-
gest that IRF-4, by modulating the efficiency of the Fas-mediated death signal, is a novel par-
ticipant in the regulation of lymphoid cell apoptosis.
Key words: SEB • Fas • polarization • AICD • caspase-8
 
Introduction
 
Apoptosis plays a crucial role in maintaining lymphocyte
homeostasis both by deleting auto-reactive cells in the pe-
riphery and by downsizing the pool of activated lympho-
cytes that have expanded during an immune response (1).
Engagement of the cell surface receptor Fas, a member of
the TNF receptor family, by its ligand, FasL (2, 3) consti-
tutes one of the critical steps in the regulation of lympho-
cyte apoptosis as demonstrated by the fact that mutations in
either Fas or Fas ligand (FasL)
 
*
 
 can result in severe lym-
phoproliferation and loss of homeostatic control in mice as
well as humans. Binding of the FasL to Fas leads to the
clustering of pre-assembled Fas trimers, resulting in a high
local concentration of Fas and in the transmission of a
strong death signal (4). Transduction of this signal requires
the assembly of a death-inducing signaling complex
(DISC), which involves the recruitment of the Fas-associ-
ated death domain (FADD) adaptor protein and of caspase-8,
a critical initiator caspase to the cytoplasmic portion of the
Fas receptor (5). Interaction of FADD with caspase-8 stim-
ulates activation of caspase-8, which activates effector cas-
pases, such as caspase-9 and -3 (6). Activation of effector
caspases by caspase-8 can either occur directly or can occur
via a mitochondrial amplification step in which release of
cytochrome 
 
c
 
 is required for the activation of caspase-9 and
-3 (7). The sequential activation of initiator and effector
caspases eventually culminates in the full execution of the
apoptotic process.
Although activated T cells express both Fas and Fas
ligand, their ability to undergo Fas-mediated apoptosis is
differentially regulated as they progress along their activa-
tion program. Indeed, early after activation, T cells are in-
sensitive to Fas-mediated apoptosis and undergo clonal ex-
pansion (8). However, as this expansion proceeds, T cells
become increasingly more sensitive to Fas-induced death
and can undergo what has been termed activation-induced
cell death (AICD; reference 9). Two major mechanisms
have been shown to control the differential sensitivity of T
cells to Fas-mediated apoptosis during the course of their
activation. The presence of intracellular inhibitors like
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Abbreviations used in this paper: 
 
AICD, activation-induced cell death;
FasL, Fas ligand; FLIP, FLICE/caspase-8 inhibitory protein; IRF-4, inter-
feron regulatory factor 4; SEB, staphylococcal enterotoxin B.T
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FLICE/caspase-8 inhibitory protein (FLIP) represents a
powerful regulatory step in this process. Recruitment of
FLIP to the DISC inhibits the activation of caspase-8 (10–
14) and changes in FLIP expression levels have been corre-
lated with sensitization of T cells to AICD (15, 16). How-
ever, recent studies have uncovered that Fas signaling can
also be controlled by the extent of polarization (or cap-
ping) of the Fas receptor within a cell (17, 18) and that the
ability of the Fas receptor to undergo polarization in T
cells depends on the state of activation of these cells. In-
deed, after 1 d of activation, T cells are resistant to Fas-
induced apoptosis and are unable to undergo Fas capping.
In contrast, T cells that have been activated for 6 d and
have acquired sensitivity to Fas-mediated apoptosis can ef-
fectively redistribute the Fas receptor to one pole of the
cell. Polarization of the Fas receptor is mediated by cyto-
skeletal reorganization and interaction of Fas with the
ERM protein, ezrin (18). The localization of Fas receptor
in caps is believed to enhance the transduction of the death
signal, thus increasing the sensitivity of lymphocytes to
AICD. Although these studies have provided insights into
the mechanisms used by T cells to modulate their suscepti-
bility to Fas-mediated death, the molecular machinery that
is responsible for implementing these processes has not
been fully characterized.
IFN regulatory factor (IRF) 4 is a member of the IRF
family of transcriptional regulators whose expression in-
creases upon activation of T cells with mitogens or anti-
CD3 antibodies (19–21). The expression of IRF-4 is pri-
marily confined to lymphocytes, and it has been proposed
that one of the distinctive roles of IRF-4 may be to confer
lineage specificity to lymphocyte responses (22). Genetic
studies have indicated that IRF-4 is a critical component of
the activation program of mature T cells (23). In addition
to profound defects in mature T cell function, IRF-4–defi-
cient mice also display a lymphoproliferative disorder with
a progressive accumulation of T and B cells in the spleen
and lymph nodes upon aging (23). This phenotype suggests
that IRF-4 may be crucial not only in regulating the acti-
vation, but also in controlling the apoptosis of lympho-
cytes. To investigate this possibility in more detail, we have
examined the Fas signaling pathway in Jurkat T cells,
which have been stably transfected with IRF-4. In these
studies, we show that expression of IRF-4 in these cells en-
hances their sensitivity to Fas-mediated apoptosis. A sys-
tematic dissection of the Fas signaling pathway in these
transfectants demonstrates that expression of IRF-4 leads to
the enhanced activation of the initiator caspase-8. Interest-
ingly, the increased sensitivity of these IRF-4–transfected
cells to Fas-dependent apoptosis is associated with an in-
creased polarization of the Fas receptor but not with
changes in FLIP levels. Consistent with these results, an ex-
amination of primary T cells from IRF-4–deficient mice
reveals that these lymphocytes not only display defects in
their ability to undergo AICD, but also exhibit diminished
Fas receptor capping. Thus, our data support a model in
which IRF-4 may serve as a critical link between the acti-
vation and the apoptotic programs of lymphocytes.
 
Materials and Methods
 
Antibodies and Reagents. 
 
The rabbit polyclonal antiserum
against IRF-4 was obtained from Santa Cruz Biotechnology, Inc.
The mAbs against cytochrome 
 
c
 
, Fas, FasL, CD4, CD62L,
CD45RB, V
 
 
 
8, and rabbit polyclonal antisera against human
caspase-8, -9, and -3, were purchased from BD Biosciences. Ag-
onistic anti–human Fas mAb (clone CH11) used to induce apop-
tosis was purchased from Upstate Biotechnology. The mAb
against FLIP antiserum (Dave-2) and the FLIP
 
long
 
 cDNA were
purchased from Qbiogene. Etoposide and staphylococcal entero-
toxin B (SEB) were purchased from Sigma-Aldrich, and the cas-
pase-8 inhibitor, z-IEDT-fmk, was purchased from Calbiochem.
MitoTracker X-rhodamine mitochondrion-selective probe and
Alexa Fluor
 
®
 
 
 
568–conjugated antibodies were purchased from
Molecular Probes.
 
Cell Lines, Stable Transfectants, and Mice. 
 
The Jurkat (human
T cell leukemia) cell line was obtained from American Type Cul-
ture Collection and maintained in IMDM supplemented with
10% FBS (Atlanta Biologicals) and 1% penicillin-streptomycin.
For preparing IRF-4 stable transfectants, the Jurkat T cells were
transfected by electroporation (960 µF, 260 V) using a BTX elec-
troporator with either a control vector (pIRES-GFP) or an IRF-4
expression vector (pIRES-GFP-IRF-4-c-myc). The transfec-
tants were selected in IMDM containing 1.5 mg/ml G418
(Promega). IRF-4 knockout mice on a C57BL6 background
were obtained from Dr. T. Mak (University of Toronto, Tor-
onto, Canada and Amgen Institute, Thousand Oaks, CA). C57/
BL6 mice were used as controls. Mice were maintained under
specific pathogen-free conditions.
 
Apoptosis Detection. 
 
Jurkat cells plated at 10
 
6
 
 cells/ml in IMDM
were cultured in the presence of the agonist anti-Fas mAb (CH-
11) at concentrations ranging from 0–1,000 ng/ml as indicated
for each experiment. Apoptosis was measured by cytofluoromet-
ric analysis by costaining with annexin V conjugate and AAD
(BD Biosciences) according to the manufacturer’s instructions.
Apoptosis was measured using a FACSCalibur™ cytometer (Bec-
ton Dickinson) and further analyzed using CellQuest software.
The number of apoptotic cells was calculated according to the
following formula: [(Percent experimental apoptosis 
 
 
 
 percent
spontaneous apoptosis)/(100 
 
 
 
 percent spontaneous apopto-
sis)] 
 
 
 
 100. Apoptosis-associated alterations in mitochondria were
assessed by flow cytometry using the MitoTracker X-rhodamine
mitochondrion-selective dye. Results were analyzed using CellQuest
software.
 
Cell Extracts and Western Blotting.
 
To quantify cytochrome 
 
c
 
released during apoptosis, mitochondrial and cytosolic prepara-
tions were performed as described previously (24). Extracts were
loaded onto 15% SDS–polyacrylamide gels, transferred to nitro-
cellulose membranes, and immunoblotted with an anti–cyto-
chrome 
 
c
 
 mAb. Western blotting for FLIP and caspase-8, -9, and
-3 were performed as described previously (25).
 
Reverse Transcriptase PCR.
 
Total RNA was extracted using
TRIzol
 
®
 
 (GIBCO BRL). The first strand cDNA synthesis was
synthesized from 5 
 
 
 
g of total RNA by Superscript II reverse
transcriptase (GIBCO BRL) using oligo (dT) primer. The PCR
primers specific for human FLIP
 
long
 
 and FasL were as follows: for-
ward primer for FLIP
 
long
 
 5
 
 
 
-GATGTCTGCTGAAGTCATC-
CATCA-3
 
 
 
; reverse primer for FLIP
 
long
 
, 5
 
 
 
-CACTACGC-
CCAGCCTTTTGG-3
 
 
 
 (26); forward primer for FasL 5
 
 
 
-
ATGTTTCAGCTCTTCCACCTACAGA-3
 
 
 
; and reverse
primer for FasL 5
 
 
 
-CCAGAGAGAGCTCAGATACGTTGAC-3
 
 
 
(27). The PCR reaction was carried out with Taq DNA poly-
merase (GIBCO BRL). Amplification was performed for 30 cy-T
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cles (30-s denaturing at 94
 
 
 
C, 30-s annealing at 55
 
 
 
C, and 90-s
extension at 72
 
 
 
C) in a thermal cycler. A human GAPDH frag-
ment was amplified under parallel conditions as a control. The
1,470-bp FLIP
 
long
 
 and 300-bp GAPDH products were run on a
1.2% agarose gel and transferred to nylon membrane. The blot
was UV cross-linked and probed with a radiolabeled human
FLIP
 
long
 
 cDNA (Qbiogene) or GAPDH cDNA probe.
 
T Cell Purification and AICD.
 
Naive CD4
 
 
 
 T cells were iso-
lated from splenocytes of IRF-4–deficient and control mice by
negative selection using the naive CD4
 
 
 
-specific T cell enrich-
ment columns (R&D Systems). The purity of naive CD4
 
 
 
 cells
was assessed by flow cytometry and was found to be 
 
 
 
90% pure.
AICD was determined as per previously published protocols (28).
In brief, naive purified CD4
 
 
 
 T cells were cultured in 6-well
plates coated with anti-CD3 mAb (BD Biosciences) at 1 
 
 
 
g/ml.
Murine IL-2 (BD Biosciences) was added at 10 ng/ml. After
72 h, cells were collected and subjected to Ficoll density centrifu-
gation. Cells were washed and cultured in duplicate wells with 10
ng/ml IL-2 in the presence or absence of plate-bound anti-CD3
mAb. Cells were collected 24 h later, washed, and fixed in 70%
ethanol at 4
 
 
 
C for 24 h. Cells were stained with propidium iodide
(PI) staining solution (PBS containing 50 
 
 
 
g/ml PI, 100 U/ml
RNase A, and 1 mg/ml glucose) for 30 min at room temperature
before FACS
 
®
 
 analysis. Apoptosis was determined by quantifica-
tion of the sub-G
 
0
 
 population. Three independent experiments
were performed and treatments were done in duplicate for each
experiment. Surface expression of Fas and FasL was determined
by FACS
 
®
 
 analysis on naive CD4
 
 
 
 T cells as described previ-
ously (28).
 
Immunofluorescence.
 
The visualization of Fas on the surface of
transfected Jurkats was performed as described previously (17). In
brief, 5 
 
 
 
 10
 
5 
 
cells were incubated with 1 
 
 
 
g/ml anti-Fas anti-
body (CH-11) for 60 min at 4
 
 
 
C followed by incubation with
Alexa Fluor
 
®
 
 568 goat anti–mouse IgM at 1:100 dilution for 60
min at 4
 
 
 
C. Cells were incubated at 37
 
 
 
C to induce capping for
30 s, 2 min, 4 min, and 30 min, and immediately fixed with 3.7%
formaldehyde for 20 min on ice. Purified naive CD4
 
 
 
 T cells
were incubated with 20 
 
 
 
g/ml antimurine Fas mAb (Jo-2) for 60
min at 4
 
 
 
C followed by incubation with Alexa Fluor
 
®
 
 568 goat
anti–hamster IgG 20 
 
 
 
g/ml for 60 min at 4
 
 
 
C. Cells were incu-
bated at 37
 
 
 
C to induce capping for 3 min and immediately fixed
with 3.7% formaldehyde for 10 min on ice. Control cells were
exposed to primary anti-Fas antibody and secondary antibody at
4
 
 
 
C, but no capping was induced at 37
 
 
 
C. Visualization of Jurkat
T cells and images were collected with a Axioplan II microscope
(Carl Zeiss MicroImaging, Inc.) using a Plan-Apochromat 100
 
 
 
/
1.4 NA objective lens, and a cooled CCD camera (model Orca-
100; Hamamatsu Photonics). Light output from the 100-W mer-
cury arc lamp was controlled using a shutter driver (model Uni-
blitz D122; Vincent Associates) and attenuated using neutral
density filters (Omega Optical Corporation). IP Lab software
(Scanalytics) was used to control the shutter driver and capture
images.
 
 
 
Primary T cells were examined by a laser scanning confo-
cal microscope (model LSM 510; Carl Zeiss MicroImaging, Inc.)
with a 100
 
 
 
/1.3 Plan-Neofluor objective lens. Optical section
thickness was 
 
 
 
1 
 
 
 
m. Image enhancement and analysis were
performed using the public domain program NIH Image 1.6 and
Adobe
 
®
 
 Photoshop 6.0. The percentage of cells displaying caps,
in which the Alexa Fluor
 
®
 
 condenses onto 
 
 
 
25% of the cell sur-
face, was determined by counting 150–250 cells.
 
Superantigen Treatment.
 
Adult mice were injected intraperito-
neally with 150 
 
 
 
g SEB (Sigma-Aldrich) or with PBS. 10 d after
injection, lymph node cells were harvested and stained with anti-
 
bodies to V
 
 
 
8
 
 
 
and CD4
 
 
 
 or to V
 
 
 
6
 
 
 
 
 
and
 
 
 
CD4
 
 
 
 (BD Bio-
sciences) to evaluate the percentage of SEB-responsive (V
 
 
 
8
 
 
 
) or
SEB-unresponsive (V
 
 
 
6
 
 
 
) CD4
 
 
 
 T cells that were present by
flow cytometry.
 
Results
 
Expression of IRF-4 in Jurkat T Cells Leads to an Enhance-
ment in Fas-mediated Apoptosis.
 
Genetic studies have dem-
onstrated the lack of IRF-4 results in lymphoproliferation
and altered homeostasis (23). Given the critical role played
by the Fas pathway in lymphocyte survival, we hypothe-
sized that IRF-4 might control the ability of lymphocytes
to undergo Fas-mediated apoptosis. To start testing this hy-
pothesis, IRF-4 was stably expressed in Jurkat cells, a hu-
man T cell line that normally lacks endogenous IRF-4. In-
dependent sets of stable transfectants were obtained, and
two of them (termed T1 and T2) were used in the follow-
ing experiments. Western blot analysis demonstrated that
both sets of IRF-4 transfectants displayed good expression
of IRF-4, whereas no IRF-4 was detected in cells trans-
fected with an empty vector (Fig. 1 A).
Fas-mediated apoptosis can be induced in Jurkat cells by
exposure to a Fas agonist monoclonal antibody (CH-11).
Thus, the different transfectants were cultured in the pres-
ence of increasing concentrations of this agonist anti-Fas
antibody and apoptosis was measured by flow cytometry
(Fig. 1 B). Starting at doses as low as 1 ng/ml anti-Fas anti-
body, the cells transfected with IRF-4 displayed a higher
susceptibility to apoptosis as compared to cells transfected
with an empty vector. Thereafter, at all doses tested, the
IRF-4 transfectants contained at least twice as many apop-
totic cells as the control transfectants. Kinetic studies fur-
ther demonstrated that the IRF-4–transfected cells under-
went apoptosis faster than the control transfectants because,
by 6 h, 
 
 
 
80% of the IRF-4–transfected cells had already
undergone apoptosis as compared to 
 
 
 
30% of the control
cells (Fig. 1 C). The level of apoptosis observed in the con-
trol transfectants was found to be comparable to that exhib-
ited by untransfected Jurkat cells, indicating that the differ-
ences observed between the IRF-4 and the control
transfectants are not due to a defect in the ability of the
control transfectants to undergo apoptosis (unpublished
data). Thus, these experiments demonstrate that the pres-
ence of IRF-4 leads to a markedly enhanced sensitivity of
lymphoid cells to Fas-mediated apoptosis.
To determine whether the presence of IRF-4 was glo-
bally affecting the susceptibility of Jurkat cells to apoptosis,
the stable transfectants were exposed to different apoptotic
inducers. One major inducer used in these studies was eto-
poside, a DNA-damaging agent that targets the mitochon-
dria to release cytochrome 
 
c
 
 in a caspase-8–independent
pathway (29). As shown in Fig. 1 D, in contrast to the ef-
fects obtained upon engagement of the Fas receptor, treat-
ment with etoposide led to similar levels of apoptosis in
both control as well as IRF-4 transfectants at all time
points tested. Furthermore, no difference in apoptosis in-
duction was detected between control and IRF-4–trans-T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
306
 
IRF-4 Modulates Fas-mediated Apoptosis
 
fected cells upon culturing them with TNF-
 
 
 
 and cyclo-
heximide, a combination known to induce apoptosis in
Jurkat cells (30; unpublished data). Thus, the enhanced
apoptosis displayed by the IRF-4 transfectants is selective
for the Fas signaling pathway.
 
Increased Activation of Caspase-8 in IRF-4 Transfectants.
 
To
start elucidating the mechanisms used by IRF-4 to modu-
late Fas-dependent apoptosis, we performed a systematic
dissection of the different components of the Fas signaling
pathway in these transfectants. We first investigated the ex-
pression levels of Fas and FasL. As shown in Fig. 2 A,
FACS
 
®
 
 analysis demonstrated that IRF-4 transfectants ex-
hibit a slight increase in Fas expression as compared to vec-
tor control. No significant differences in FasL levels be-
tween control and IRF-4 transfectants were noted either
by semi-quantitative PCR (Fig. 2 B) or by Western blot-
ting (unpublished data). Thus, the presence of IRF-4 does
not significantly alter FasL expression and exerts only mini-
mal effects on Fas receptor levels in these cells, suggesting
that an alternative mechanism may account for the striking
increase in Fas-induced apoptosis observed in the IRF-4–
transfected cells.
Given that caspase-8 acts as a critical initiator of the Fas-
mediated signaling cascade, the activation of this caspase
was examined next (5, 31). Jurkat transfectants were ex-
posed to 100 ng/ml anti-Fas mAb for various durations,
whole cell extracts were prepared and activation of specific
caspases was examined by Western blot analysis (Fig. 3 A).
These experiments demonstrated that in the IRF-4 trans-
fectants, there is a striking increase in caspase-8 activation as
compared to the control. This increased activation was
most noticeable at 2–3 h. After 6 h of exposure to the anti-
Fas antibody, the IRF-4 transfectants showed a decrease in
caspase-8 activation most likely due to the fact that by this
time the great majority of IRF-4–transfected cells had al-
ready undergone apoptosis (Fig. 1 C). To confirm the re-
quirement for caspase-8 in the IRF-4–mediated apoptotic
process, cells were cultured with a caspase-8–specific inhib-
Figure 1. Expression of IRF-4 enhances Fas-mediated apoptosis. (A) Western blot
analysis of IRF-4 in whole cell lysates of Jurkat cells stably transfected with an either
empty vector or an IRF-4 expression vector. The blot was first analyzed using an
anti–IRF-4 antibody (top), it was later stripped and reprobed with a  -actin anti-
body to ensure for equal loading (bottom). (B) Jurkat-transfected cells were incu-
bated for 16 h with the indicated concentrations of an anti-Fas mAb (CH11). After
this incubation, cells were harvested and analyzed by flow cytometry for apoptosis by
annexin V and AAD staining. (B–D) Data shown are representative of three inde-
pendent experiments and were performed on two independent sets of transfectants.
Transfected Jurkat cells were cultured with 100 ng/ml anti-Fas mAb for 0, 6, or 16 h.
Cells were collected at the distinct time points and apoptosis was measured as de-
scribed in B. The data shown are representative of three independent experiments
and were performed on two independent sets of transfectants. Transfected Jurkat
cells were cultured with 100 ng/ml anti-Fas mAb or with 10  g/ml etoposide for 0,
3, 6, or 16 h. After this incubation, cells were harvested and apoptosis was measured
as described in B. Data are representative of three independent experiments (open
bars). Control Jurkat transfectants; (solid bars) IRF-4 Jurkat transfectants.T
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itor, z-IEDT–fmk (32). As shown in Fig. 3 B, pretreatment
with the caspase-8 inhibitor blocked Fas-mediated apopto-
sis in both IRF-4 and control transfectants in a dose-
dependent manner. Not surprisingly, given the higher level
of caspase-8 activation displayed by the IRF-4–transfected
cells, a higher dose of the caspase-8 inhibitor was required
to reach optimal inhibition of Fas-mediated apoptosis in
the IRF-4 transfectants. Thus, these results indicate that
enhanced activation of caspase-8 is a critical step in the in-
creased susceptibility to the Fas-mediated cell death exhib-
ited by IRF-4 transfectants.
To confirm that the enhanced activation of caspase-8
observed in IRF-4 transfectants led to an increase in the ac-
tivation of downstream caspases, we examined the activa-
tion of caspase-9 and -3. Caspase-9 is cleaved in the mito-
chondrial pathway downstream of caspase-8 (33, 34), and
caspase-3 can be cleaved by both caspase-8 and -9 (35). As
shown by Western blot analysis, caspase-9 activation is sig-
nificantly increased at 2 h in IRF-4–transfected cells as
compared to control cells (Fig. 3 C). Again, due to the
overall increased cell death observed in the IRF-4 transfec-
tants after 6 h of treatment with the anti-Fas mAb, a de-
crease in the activation of caspase-9 in the IRF-4 transfec-
tants was noted at this time point. A significant decrease in
procaspase-3 was also observed by Western blot, suggesting
that caspase-3 activation was similarly enhanced (Fig. 3 C).
Numerous studies have shown that in Jurkat cells,
caspase-8 activation is followed by disruption of mito-
chondrial function (36–38) and subsequent cytochrome 
 
c
 
release into the cytosol. Given that the activation of
caspase-8 is greatly enhanced in IRF-4–transfected cells,
the integrity of the mitochondria after Fas stimulation of
these cells was assessed by measuring the transmembrane
potential and the release of cytochrome 
 
c
 
. FACS
 
®
 
 analysis
using Mitotracker, a dye whose incorporation into the cell
depends on mitochondrial integrity, demonstrated that mi-
tochondrial membrane potential decreased upon incuba-
tion of the cells with the anti-Fas antibody (Fig. 4 A). The
Figure 2. Expression of Fas and FasL in
control and IRF-4 transfectants. (A) Surface
expression of the Fas receptor in Jurkat
transfectants. Cells from control and IRF-4–
transfected cells were stained with either a
PE-labeled isotype-matched control Ab (I)
or a PE-labeled anti-Fas IgG1 antibody (II).
Cells were subsequently analyzed by flow
cytometry. Control vector transfectants (solid lines); IRF-4 transfectants
(dotted lines). (B) RT-PCR analysis for FasL expression in IRF-4 Jurkat
transfectants. Total RNA was isolated from control and IRF-4–trans-
fected cells, and RT-PCR was performed using primers specific for FasL
(top) or GAPDH (bottom). PCR products were separated by electro-
phoresis on a 2% agarose gel.
Figure 3. Stable expression of IRF-4 leads to increased activation of
caspase-8 and of downstream caspases upon engagement of the Fas recep-
tor. (A) Cells from control and IRF-4 transfectants were cultured with
the anti-Fas mAb CH-11 at 100 ng/ml and harvested after the indicated
periods of incubation. Total cell lysates were separated by 7% SDS–poly-
acrylamide gel electrophoresis, and caspase-8 processing was detected by
immunoblotting with an anti–human caspase-8 Ab (top). Vector refers to
the control Jurkat transfectants, whereas IRF-4 refers to the IRF-4 stable
Jurkat transfectants. The procaspase-8 form at 55 kD and the active
caspase-8 at 40 kD are indicated by arrows. Blots were stripped and re-
probed with a  -actin Ab as a loading control (bottom). (B) Open bars:
control Jurkat transfectants; solid bar: IRF-4 Jurkat transfectants. Vector
control and IRF-4 transfectants were cultured with or without z-IETD-
fmk, a caspase-8 inhibitor, for 1 h at 37 C at 1-, 10-, or 100- M concen-
tration followed by the addition of 100 ng/ml anti-Fas mAb for 6 h. After
this incubation, cells were harvested and analyzed by flow cytometry for
apoptosis as indicated in Fig. 1 B. Addition of z-IETD fmk alone had no
effect on the viability of the cells (unpublished data). (C) Cells were incu-
bated with 100 ng/ml anti-Fas mAb CH-11 and harvested after the indi-
cated periods of incubation. Total cell lysates were separated by SDS–
polyacrylamide gel electrophoresis, and caspase-9 and -3 processing was
detected by immunoblotting with antibodies against either active human
caspase-9 (top) or procaspase-3 (middle). The active caspase-9 form at 37
kD and the procaspase-3 form are indicated by arrows. Blots were
stripped and reprobed with a  -actin Ab as a loading control (bottom).T
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loss of mitochondrial membrane potential occurred faster
in the IRF-4 transfectants as compared to control cells.
This finding was confirmed by examining the release of
cytochrome 
 
c
 
 from the mitochondria into the cytosol after
engagement of the Fas receptor. As shown in Fig. 4 B,
Western blot analysis with a cytochrome 
 
c
 
 antibody re-
vealed that the IRF-4–transfected cells displayed a greater
release of cytochrome 
 
c
 
 into the cytosol after anti-Fas anti-
body treatment as compared to control cells. Therefore, all
these studies indicate that the presence of IRF-4 leads to a
significant increase in caspase-8 activation, which, in turn,
markedly enhances the activation of further downstream
effectors of the Fas signaling pathway.
Presence of IRF-4 Does Not Significantly Affect FLIP Levels
but Leads to an Increased Polarization of the Fas Receptor. Re-
cent studies have demonstrated that FLIP, which can com-
plex with caspase-8 and prevent its activation (11, 12), is a
critical regulator of the sensitivity of lymphocytes to Fas-
mediated apoptosis. Given the enhanced caspase-8 activa-
tion exhibited by the IRF-4 transfectants, we decided to
investigate whether the presence of IRF-4 could affect the
expression of FLIP. As shown in Fig. 5, semi-quantitative
RT-PCR failed to demonstrate significant differences in
the mRNA levels of one of the major isoforms of FLIP,
FLIPlong, between the IRF-4 and the control transfectants.
Similar results were obtained for the other major FLIP iso-
form, FLIPshort (unpublished data). Western blotting with
an antibody against FLIP further confirmed these results
(unpublished data). Therefore, IRF-4 does not significantly
affect the expression of FLIP in Jurkat cells.
The polarization (or capping) of the Fas receptor has re-
cently been proposed to function as a novel regulatory
mechanism for controlling the sensitivity of activated lym-
phocytes to Fas-mediated apoptosis (18). The ability of the
IRF-4 transfectants to undergo Fas capping by cross-link-
ing with an anti-Fas antibody was examined. Before induc-
tion of capping, Fas was uniformly distributed around the
cell surface (Fig. 6 A). Both control and IRF-4 transfectants
displayed a similar staining pattern under these conditions.
However, once cross-linking of Fas was induced, the IRF-4
transfectants displayed a markedly enhanced ability to un-
dergo Fas capping as compared to the control cells (Fig. 6
A). This enhancement was noted at two distinct time
points, 2 and 4 min (Fig. 6 B). After 4 min of cross-linking,
the Fas receptor was internalized into the cells. Thus, these
data suggest that the presence of IRF-4 enhances the ability
of the Fas receptor to undergo polarization, thus possibly
allowing for a more efficient and organized transduction of
the Fas-mediated death signal.
Lymphocytes from IRF-4–deficient Mice Demonstrate a De-
creased Sensitivity to AICD Coupled with Impairments in the
Polarization of the Fas Receptor. To ascertain the physiological
contribution of the IRF-4–mediated effects of lymphocyte
apoptosis, we next investigated the Fas pathway in lympho-
cytes from IRF-4–deficient mice. Purified naive CD4  T
cells from control and IRF-4–deficient mice were activated
for 72 h with anti-CD3 and anti-CD28 in the presence of
IL-2. Fas and FasL levels on unstimulated as well as stimu-
lated cells were measured by FACS® analysis. As shown in
Fig. 7 A, no significant alterations in the basal or inducible
levels of FasL in T cells from IRF-4–deficient mice were
noted. Furthermore, the lack of IRF-4 resulted only in a
slight decrease in the inducibility of the Fas receptor.
Given that expression of IRF-4 in Jurkat cells signifi-
cantly enhanced the ability of the Fas receptor to undergo
Figure 4. Mitochondrial dysfunction after engagement of the Fas recep-
tor is enhanced in the presence of IRF-4. (A) Jurkat control and IRF-4–
transfected cells were incubated with the anti-Fas mAb at 100 ng/ml for
the indicated times. After this incubation, cells were harvested, stained
with the MitoTracker X-rhodamine mitochondrion-selective dye, and an-
alyzed by flow cytometry for loss of mitochondrial membrane potential.
Cells that lost staining with the mitochondrial-specific dye were consid-
ered as cells with loss of mitochondrial membrane potential. (B) Cells were
cultured with 100 ng/ml anti-Fas mAb CH-11 and harvested after the in-
dicated periods of incubation. Cytosolic extracts were separated by SDS–
polyacrylamide gel electrophoresis and cytochrome c release was detected
by immunoblotting with an antibody against human cytochrome c (top).
The position of cytochrome c at 15 kD is indicated by arrows. Blots were
stripped and reprobed with a  -actin Ab as a loading control (bottom).
Figure 5. Expression of IRF-4 does not significantly affect FLIP levels.
Total RNA from control and IRF-4 stable transfectants was isolated and
reverse transcribed using oligo dT primers. PCR was performed on two-
fold serial dilutions of the first-strand cDNA using primers specific for
FLIPlong or GAPDH. The PCR products were electrophoresed on a 2%
agarose gel and transferred to a nylon membrane. The blot was probed
with 32P-labeled full-length FLIP cDNA (top) followed by probing with
GAPDH cDNA (bottom).T
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capping, we tested whether naive CD4  T cells from IRF-
4–deficient mice display impairments in the polarization of
the Fas receptor (Fig. 7 B). Before cross-linking the Fas re-
ceptor, both control and IRF-4–deficient T cells displayed
a similar uniform pattern of surface staining of the Fas re-
ceptor. However, upon cross-linking of the Fas receptor,
 60% of T cells from control mice displayed capping of
the Fas receptor, whereas only  10% of T cells from IRF-
4–deficient mice were able to polarize the Fas receptor
(Fig. 7, B and C). Thus, consistent with our results in the
Jurkat transfectants, the lack of IRF-4 affects the ability of
T cells to redistribute the Fas receptor upon cross-linking.
To determine whether the defect in Fas polarization was
coupled to a differential susceptibility to undergo apoptosis,
we examined whether naive CD4  T cells from IRF-4–
deficient mice were resistant to AICD. As shown in Fig. 8
A, CD4  T cells from IRF-4–deficient mice exhibited a
markedly diminished ability to undergo AICD (Fig. 8 A). In
agreement with these findings, an examination of the CD4 
T cells accumulating in the lymphoid tissues of aging IRF-
4–deficient mice revealed an increased number of T cells
bearing the phenotype of previously experienced T cells
(CD44high, CD45RBlow, and CD62Llow) (Fig. 8 B and un-
published data). Furthermore, we treated mice with the su-
perantigen, SEB, which leads to the elimination of V 8 
(superantigen responsive) T cells (39) in a Fas-dependent
manner (40, 41). As shown in Fig. 8 C, upon SEB injection,
IRF-4–deficient mice displayed a decreased ability to elimi-
nate V 8 CD4 -responsive cells as compared to wild-type
mice. As expected, SEB injection did not lead to the elimi-
nation of the V 6 CD4  T cell population (which is not
responsive to SEB) in either wild-type or IRF-4–deficient
mice (unpublished data). Thus, these data support the no-
tion that IRF-4 plays a physiologic role in the ability of the
immune system to eliminate activated cells.
Discussion
The Fas signaling pathway has been shown to be critical
in helping the immune system maintain a state of equilib-
rium (9). Because mice deficient in IRF-4 display distur-
bances in lymphocyte homeostasis (23), in these studies we
have investigated whether IRF-4 regulates the ability of
lymphocytes to undergo Fas-dependent apoptosis. Our re-
sults indicate that expression of IRF-4 enhances the suscep-
tibility of lymphocytes to undergo Fas-induced cell death.
Consistent with these findings, lymphocytes from IRF-4–
deficient mice exhibit an impaired ability to undergo
AICD, a well-known Fas-mediated event, as well as defects
in the SEB-mediated elimination of V 8 CD4  T cells
(42–44). The IRF-4–mediated effect is selective for the Fas
pathway because expression of IRF-4 does not alter the
sensitivity of Jurkat cells to other apoptotic inducers. The
critical target of the IRF-4–mediated effects is the activa-
tion of caspase-8, a key initiator caspase in the Fas signaling
pathway (5, 31). Indeed, stable expression of IRF-4 leads
to a marked increase in caspase-8 activation upon Fas en-
gagement and the addition of a caspase-8 inhibitor blocks
Fas-mediated cell death in IRF-4–transfected cells. The in-
creased caspase-8 activation detected in the IRF-4 stable
transfectants is accompanied by a commensurate increase in
mitochondrial dysfunction and in the activation of effector
caspases, i.e., in steps known to be downstream of caspase-8
activation. Together, these data indicate that IRF-4 can
control lymphocyte apoptosis by modulating one of the
critical initiating events in the Fas signaling cascade.
One of the most interesting features of our work is that
the IRF-4–mediated effects on lymphocyte apoptosis are
associated with changes in the ability of the Fas receptor to
Figure 6. Stable expression of IRF-4 in Jurkat cells leads to enhanced
polarization of the Fas receptor. (A) 106 Jurkat transfectants were exposed
first to 1  g/ml anti-Fas Ab at 4 C for 60 min, and then to Alexa Fluor®
568–conjugated secondary antibody. Cells were warmed at 37 C for 30 s,
2 min, 4 min, and 30 min, harvested, fixed with 3.7% formaldehyde, and
mounted onto slides. Unstimulated control cells (no cap) were exposed to
the anti-Fas Ab and the secondary antibody at 4 C only. Cells were ex-
amined with a microscope using a Plan-Apochromat 100 /1.4 NA ob-
jective lens, and a cooled CCD camera. Photos were taken of no capping
samples and of the maximum capping time point of 2 min in both control
and IRF-4 transfectants. Panels I and II are no capping controls of vector
and IRF-4, respectively. Panels III and IV are representative of control and
IRF-4 transfectant cells, respectively, that have undergone Fas capping for
2 min. (B) Quantitation of Fas capping in the distinct Jurkat transfectants.
Fas capping was quantitated as described in Materials and Methods.
150–250 cells were analyzed at each time point.T
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undergo polarization (or cap). These effects were noted
both in the Jurkat IRF-4 transfectants (Fig. 6) as well as in
primary T cells from IRF-4–deficient mice (Fig. 7). Polar-
ization of Fas is believed to enhance lymphocyte suscepti-
bility to Fas-mediated death by facilitating Fas clustering
and enhancing the transmission of the Fas signal (17, 18).
The exact mechanism by which IRF-4 promotes Fas polar-
ization is presently under investigation. Redistribution of
Fas on the cell surface has been shown to require associa-
tion of Fas with the cytoskeleton via interaction with ezrin,
a protein known to link plasma membrane proteins to the
actin cytoskeleton (18). Thus, it is conceivable that IRF-4
may control the expression of specific cytoskeletal compo-
nents that are required for this process. Indeed, preliminary
results from a microarray analysis performed in our labora-
tory suggest that the presence of IRF-4 can modulate the
expression of a number of genes involved in cytoskeletal
rearrangement (unpublished observations). Furthermore,
such a mechanism would be consistent with recent studies
on IFN consensus sequence-binding protein, another
member of the IRF family highly homologous to IRF-4.
ICSBP, which is critical for myeloid cell differentiation and
function, was shown to control the expression of genes in-
volved in the regulation of macrophage spreading and ad-
hesion (45). Thus, it is tempting to speculate that these two
members of the IRF family, IRF-4 and ICSBP, play a dis-
tinctive role in the control of the cytoskeletal organization,
respectively, of lymphocytes and macrophages.
Our current findings support the notion that the suscep-
tibility of lymphocytes to AICD can be determined not
only by the levels of expression of Fas and its ligand, but
also by the precise spatial arrangement of the Fas receptor
within the cell surface. It is indeed becoming increasingly
evident that efficient and sustained signaling by many re-
ceptors requires the clustering of these receptors together
with associated signaling molecules in precisely organized
molecular complexes. This has been most notably de-
scribed for the TCR (46), which upon contact with the
appropriate MHC–peptide complex undergoes a dynamic
redistribution to form what has been termed an immuno-
Figure 7. CD4  T cells from IRF-4–deficient mice exhibit normal Fas and FasL ex-
pression but reduced polarization of the Fas receptor. (A) FACS® analysis of Fas and FasL
expression in purified CD4  T cells from wild-type (IRF-4  / ) or IRF-4–deficient
(IRF-4  / ) mice, which were either left unstimulated (solid lines) or stimulated with 1
 g/ml anti-CD3 and 1  g/ml anti-CD28 Abs plus 10 ng/ml IL-2 for 3 d (dotted lines). No
differences were noted by staining with isotype-matched controls performed in parallel sam-
ples (unpublished data). (B) I and II are no capping controls of control and IRF-4–deficient
T cells, respectively. III and IV are representative of control and IRF-4–deficient T cells, re-
spectively, that have undergone Fas capping for 3 min. Fas capping. After activation, 106 pu-
rified naive CD4  T cells were exposed first to 20  g/ml anti-Fas at 4 C for 60 min, and
then to Alexa Fluor® 568–conjugated secondary antibody. Cells were warmed at 37 C for 3
min, harvested, fixed with 3.7% formaldehyde, and mounted onto slides. No capping con-
trol cells were exposed to anti-Fas and secondary antibody at 4 C only. Cells were examined
using a laser scanning confocal microscope with a 100 /1.3 Plan-Neofluor objective lens.
Optical section thickness was  1  m. Representative images were taken of no capping
samples and of the maximum capping time point of 3 min. Capped T cells are indicated by
arrows, whereas partially capped or patched T cells are indicated by asterisks. (C) Quantitation of Fas capping. Cells were stimulated as described in B. Fas
capping was quantified using a fluorescent microscope as described in Fig. 6 B. Cells were considered to have Fas caps if the staining pattern showed po-
larization that condensed to  25% of the cell surface. The experiment is representative of three separate experiments, which were conducted on
5–8-wk-old mice. Isotype-matched controls were also performed and were comparable to control no capped staining (unpublished data).T
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logical synapse (47, 48). Interestingly, formation of this im-
munological synapse is profoundly dependent on cytoskel-
etal reorganization (49–53); similarly, Fas polarization
requires the activity of the ERM protein ezrin (54–56).
Given that clustering of both Fas and T cell receptors may
involve common cytoskeletal components, it will be inter-
esting to determine whether the presence or absence of
IRF-4 affects the redistribution of the TCR and/or of ad-
ditional receptor complexes.
Although our studies indicate that presence of IRF-4 en-
hances the susceptibility of lymphocytes to Fas-mediated
death, the role of IRF-4 in this process is likely to be under
complex regulation because a large proportion of T and B
lymphoid malignancies express IRF-4 (57-61). Because re-
sistance to Fas-mediated apoptosis is a common mechanism
used by tumors to evade the immune system, it will be in-
teresting to determine whether the IRF-4–mediated effects
on the susceptibility to Fas-mediated death are selectively
bypassed in IRF-4–expressing tumors. Interestingly, we
have reported previously that IRF-4 function can be mod-
ulated by the presence of BCL-6 (25), a Krüppel-type zinc
finger transcriptional repressor, whose deregulation is a
common event in non-Hodgkin’s lymphoma (62). Given
that coexpression of IRF-4 and BCL-6 has been detected
in 50% of non-Hodgkin’s lymphomas (63, 64), it is possible
that BCL-6 may interfere with the IRF-4–mediated effects
on Fas-dependent apoptosis thus potentially leading to
pathophysiological consequences. Further research will be
needed to elucidate the full implications of the IRF-4–
BCL-6 interaction in lymphocyte apoptosis.
Our work is consistent with a model whereby IRF-4
serves as a molecular link between the activation program
of lymphocytes and their ability to undergo AICD. Such a
role might explain why the lack of IRF-4 results not only
in defects in lymphocyte activation, but also in progressive
lymphoaccumulation (23). The critical question remains
whether the dual role of IRF-4 in the activation and death
of lymphocytes can be differentially modulated. Given that
Figure 8. IRF-4–deficient mice exhibit impaired AICD and an accumulation
of CD4  T cells with an “experienced” phenotype upon aging. (A) AICD. Pu-
rified naive CD4  T cells were activated with 1  g/ml anti-CD3 plus IL-2 for
3 d, and then harvested. The cells were restimulated with either IL-2 alone or
IL-2   anti-CD3 at the indicated doses for 24 h. The percentage of apoptotic
cells was determined by quantification of the sub-G0 population by FACS®. Each
assay was conducted in duplicate. The experiment is representative of three sepa-
rate experiments. (B) Flow cytometric analysis of spleen cells from 12–15-wk-old
wild-type and IRF-4–deficient mice. Single cell suspensions of splenocytes were
stained with anti-CD4 versus anti-CD45RB (top) or anti-CD4 versus CD62L
(bottom). Percentages of positive cells within each quadrant are indicated. (C)
Mice (four per treatment) were injected with either PBS or SEB. After 10 d, the
percentage of V 8 CD4  (SEB responsive) T cells in lymph nodes was deter-
mined by flow cytometry. Each symbol represents an individual mouse. Bars rep-
resent the mean of each group of four mice. The number of V 6 CD4  (SEB
unresponsive) T cells was also determined by flow cytometry as a control, and
it was found not to be affected by SEB treatment in either wild-type or IRF-4–
deficient mice (unpublished data).T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
312 IRF-4 Modulates Fas-mediated Apoptosis
IRF-4 is well-known to interact with additional cofactors
(65–68), an attractive hypothesis is that the presence or ab-
sence of specific partners may modulate the ability of IRF-4
to function in the two pathways. We have proposed previ-
ously that one of the distinctive features of IRF-4 may be
to function as an “integrator” in the course of lymphocyte
activation (22). Such an integrator, possibly via its ability to
associate with different cofactors, may help lymphocytes to
summate the information provided to them by distinct in-
coming signals and may thus be ideally positioned to play a
central role in the life and death decisions made by lym-
phocytes.
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